Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Dec 3:15:163.
doi: 10.1186/s12872-015-0153-7.

C-Reactive protein reactions to glucose-insulin-potassium infusion and relations to infarct size in patients with acute coronary syndromes

Hadeel Alkofide  1   2 , Gordon S Huggins  3 , Joni R Beshansky  4   5 , Robin Ruthazer  4   6 , Inga Peter  7 , Madhab Ray  1 , Jayanta T Mukherjee  1   6 , Harry P Selker  8   9
Affiliations
Randomized Controlled Trial

C-Reactive protein reactions to glucose-insulin-potassium infusion and relations to infarct size in patients with acute coronary syndromes

Hadeel Alkofide et al. BMC Cardiovasc Disord. .

Abstract

Background: Some benefits of glucose-insulin-potassium (GIK) in patients with acute coronary syndromes (ACS) may be from an anti-inflammatory effect. The primary aim of this study was to assess the impact of GIK administration early in the course of ACS on inflammatory marker C-reactive protein (CRP) levels. A secondary aim was to investigate the association between CRP and 30-day infarct size.

Methods and results: Retrospective analysis of participants with ACS randomly assigned to GIK or placebo for at least 8 h in the IMMEDIATE Trial biological mechanism cohort (n = 143). High sensitivity CRP (hs-CRP) was measured at emergency department presentation, and 6 and 12 h into infusion. Logarithmically transformed hs-CRP values at 12-hours were lower with GIK vs. placebo (mean =0.65 mg/L in GIK, 0.84 mg/L in placebo), with a marginal trend toward significance (P = 0.053). Furthermore, using mixed models of hs-CRP, time, and study group, there was a significant increase in hs-CRP levels over time, but the rate of change did not differ between treatment arms (P = 0.3). Multivariable analysis showed that an elevation in hs-CRP, measured at 12 h, was an independent predictor of 30-day infarct size (β coefficient, 6.80; P = 0.04) using sestamibi SPECT imaging.

Conclusions: The results of this study show no significant effect of GIK on hs-CRP. In addition our results show that in patients with ACS, hs-CRP measured as early as 12 h can predict 30-day infarct size.

Trial registration: ClinicalTrials.gov NCT00091507.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
hs-CRP Levels per Treatment Arm. Time course of mean ± SEM hs-CRP at initial, 6 h and 12 h per treatment arm. GIK indicates glucose-insulin-potassium; Hs-CRP high sensitivity C-reactive protein. * P = 0.053 between groups at 12 h (independent sample t-test). † P˂0.01 within group differences between initial and 6 h, 6 h and 12 h, and initial and 12 h (paired sample t-test). Initial time represents the first hs-CRP measurement (median = 2.5 h)
See this image and copyright information in PMC

References

    1. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J. 2004;25(8):634–41. doi: 10.1016/j.ehj.2004.02.018. - DOI - PubMed
    1. Hadj A, Pepe S, Marasco S, Rosenfeldt F. The principles of metabolic therapy for heart disease. Heart Lung Circ. 2003;12(Suppl 2):S55–62. doi: 10.1016/S1443-9506(03)90391-X. - DOI - PubMed
    1. Schofield RS, Hill JA. Role of metabolically active drugs in the management of ischemic heart disease. Am J Cardiovasc Drugs. 2001;1(1):23–35. doi: 10.2165/00129784-200101010-00003. - DOI - PubMed
    1. Hadj A, Pepe S, Rosenfeldt F. The clinical application of metabolic therapy for cardiovascular disease. Heart Lung Circ. 2007;16(Suppl 3):S56–64. doi: 10.1016/j.hlc.2007.04.001. - DOI - PubMed
    1. Sodi-Pallares D, Testelli MR, Fishleder BL, Bisteni A, Medrano GA, Friedland C, et al. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am J Cardiol. 1962;9:166–81. doi: 10.1016/0002-9149(62)90035-8. - DOI - PubMed

Publication types

Associated data